Raltitrexed and Paclitaxel for Gastric or Gastroesophageal Junction Adenocarcinoma
Status:
Completed
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
This is a single-arm clinical trial.The purpose of this study is to evaluate the efficacy and
safety of Raltitrexed and Paclitaxel as second-line chemotherapy for patients with
unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma .The primary
endpoint of this study is objective response rate.The secondary endpoint of this study is
safety,progression-free survival and overall survival.